BriaCell Therapeutics Corp. announced the addition of immunology expert, Cara L. Haymaker, Ph.D., to its Scientific Advisory Board, effective immediately. Additionally, Dr. Bill Williams, BriaCell's President & CEO, has been selected to lead the upcoming special joint issue of the peer-reviewed journals, Frontiers in Pharmacology and Frontiers in Oncology with the research topic of 'Targeted Immunotherapy for Cancer'. Dr. Cara Haymaker is an assistant professor at Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center. She has been appointed as Director, CCSG Oncology Research and Immunomonitoring Core, Department of Translational Molecular Pathology, Division of Pathology and Lab Medicine since 2018, and as Faculty Member, Translational Molecular Pathology Immunoprofiling Laboratory (TMP-IL) since 2016 at MD Anderson.